The disruptive nature of personalized medicine technologies: Implications for the health care system

Public Health Genomics

Volumn 12, Issue 3, 2009, Pages 180-184

  Carlson, R J ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Disruptive technology; Genomics; Policy

Indexed keywords

COST EFFECTIVENESS ANALYSIS; GENOMICS; HEALTH CARE; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HUMAN; PHARMACOGENOMICS; PRIORITY JOURNAL; PRIVATE HEALTH INSURANCE; PUBLIC HEALTH; SHORT SURVEY; ARTICLE; HEALTH CARE DELIVERY; HEALTH SERVICE; METHODOLOGY; PHARMACOGENETICS; POLICY;

DELIVERY OF HEALTH CARE; HUMANS; PERSONAL HEALTH SERVICES; PHARMACOGENETICS; PUBLIC POLICY;

EID: 64549139802     PISSN: 16624246     EISSN: None     Source Type: Journal    
DOI: 10.1159/000189631     Document Type: Short Survey

References (4)

1. Winstein K: Study: more complexity in tailoring cancer drugs. The Wall Street Journal, February 28, 2008.
2. Christensen CM, Bohner R, Kenagy J: Will disruptive innovations cure health care? Harvard Business Review, September-October 2000, pp 102-112.
3. Morris W. Foster, Department of Anthropology, University of Oklahoma, Norman, Oklahoma; Correspondence to M.W. F. from Richard R. Sharp, Department of Bioethics, Cleveland Clinic, Cleveland, Ohio, USA.
4. Burke W, Welch WG: What's in your genes - you don't want to know yet. The Washington Post, May 11, 2008.